Phase 1 first-in-human trial of MTB-9655, the first oral inhibitor of ACSS2, in patients with advanced solid tumors.

被引：0
|
作者：
Perets, Ruth
Geva, Ravit
McKean, Meredith
Goutopoulos, Andreas
Erez, Omri
Phadnis, Monica
Youssoufian, Hagop
Schwartz, Brian E.
Kansra, Vikram
Fattaey, Ali
机构：
[1] Rambam Hlth Care Campus, Haifa, Israel
[2] Tel Aviv Sourasky Med Ctr, Div Oncol, Tel Aviv, Israel
[3] Sarah Cannon Res Inst, Tennessee Oncol, PLLC, Nashville, TN USA
[4] Metabomed, Cambridge, MA USA
[5] Metabomed, Yavne, Israel
[6] Metabomed, Boston, MA USA
[7] Curis Inc, Lexington, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20609
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Preclinical characterization of MTB-9655, a first-in-class, clinical stage ACSS2 inhibitor
    Goutopoulos, Andreas
    Amanati, Iris
    Fattaey, Ali
    Hay-Koren, Avital
    Nakache, Philippe
    Erez, Omri
    Kovalerchik, Dimitri
    Paz, Dikla
    Botti, Simone
    Oppenheimer, Hannah
    Fainer, Irit
    [J]. CANCER RESEARCH, 2022, 82 (12)
  • [2] First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors.
    De Bono, Johann Sebastian
    Mina, Lida A.
    Gonzalez, Michael
    Curtin, Nicola J.
    Wang, Evelyn
    Henshaw, Joshua W.
    Chadha, Manpreet
    Sachdev, Jasgit C.
    Matei, Daniela
    Jameson, Gayle S.
    Ong, Michael
    Basu, Bristi
    Wainberg, Zev A.
    Byers, Lauren Averett
    Chugh, Rashmi
    Dorr, Andrew
    Kaye, Stanley B.
    Ramanathan, Ramesh K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] A first-in-human phase 1 dose-escalation trial of the oral HIF-2a inhibitor PT2977 in patients with advanced solid tumors.
    Papadopoulos, Kyriakos P.
    Jonasch, Eric
    Zojwalla, Naseem J.
    Wang, Keshi
    Bauer, Todd Michael
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [4] A first-in-human phase I trial of AR-12, a PDK-1 inhibitor, in patients with advanced solid tumors.
    Mateo, Joaquin
    De Bono, Johann Sebastian
    Ramanathan, Ramesh K.
    Lustberg, Maryam B.
    Zivi, Andrea
    Basset, Dawn
    Ng, Matthew
    Young, Anna-Mary
    Garrett, Michelle
    Decordova, Shaun
    Raynaud, Florence I.
    Yap, Timothy Anthony
    Zukiwski, Alexander A.
    Proniuk, Stefan
    Shapiro, Charles L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [5] First-in-human phase 1 study of DS-1062a in patients with advanced solid tumors.
    Sands, Jacob M.
    Shimizu, Toshio
    Garon, Edward B.
    Greenberg, Jonathan
    Guevara, Ferdinand M.
    Heist, Rebecca Suk
    Kobayashi, Fumiaki
    Noguchi, Yutaka
    Okajima, Daisuke
    Tajima, Naoyuki
    Spira, Alexander I.
    Yamamoto, Noboru
    Lisberg, Aaron Elliott
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [6] A first-in-human, phase 1 study evaluating oral TACC3 inhibitor, AO-252, in advanced solid tumors.
    Dumbrava, Ecaterina Elena
    Kennon, Amber Michelle
    Balema, Wintana A.
    Lim, Chaemin
    Vempati, Sridhar
    Stergiopoulos, Sotirios
    Richardson, Debra L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [7] First-in-human study of TAS-115, a novel oral MET/VEGFR inhibitor, in patients with advanced solid tumors.
    Matsubara, Nobuaki
    Shitara, Kohei
    Naito, Yoichi
    Kuboki, Yasutoshi
    Ohno, Izumi
    Takahashi, Hideaki
    Bando, Hideaki
    Kojima, Takashi
    Fuse, Nozomu
    Yamazaki, Tomoko
    Hirayama, Naoki
    Fujita, Hidenori
    Nishida, Toshirou
    Doi, Toshihiko
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [8] CHIR-258: first-in-human phase 1 dose escalating trial of an oral, selectively targeted tyrosine kinase inhibitor in patients with solid tumors.
    Sarker, D
    Evans, J
    Judson, I
    Butzberger, P
    Marriott, C
    Morrison, R
    Vora, J
    Heise, C
    Hannah, A
    de Bono, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 202S - 202S
  • [9] First-in-human, first-in-class phase 1 study of a novel oral multi-AGC kinase inhibitor AT13148 in patients (pis) with advanced solid tumors.
    Kumar, Rajiv
    Mateo, Joaquin
    Smith, Alan D.
    Khan, Khurum Hayat
    Ruddle, Ruth
    Swales, Karen E.
    Decordova, Shaun
    Backholer, Zoe
    Jones, Paul
    Tran, Christine
    Seeramraddi, Satyanarayana
    McLeod, Robert
    Yap, Timothy Anthony
    Raynaud, Florence I.
    Garrett, Michelle D.
    Banerji, Udai
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [10] First-in-human phase I study of the ALK inhibitor LDK378 in advanced solid tumors.
    Mehra, Ranee
    Camidge, D. Ross
    Sharma, Sunil
    Felip, Enriqueta
    Tan, Daniel Shao-Weng
    Vansteenkiste, Johan F.
    De Pas, Tommaso Martino
    Kim, Dong-Wan
    Santoro, Armando
    Liu, Geoffrey
    Goldwasser, Meredith
    Dai, David
    Radona, Marietta
    Boral, Anthony
    Shaw, Alice Tsang
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345